Size-dependent heterogeneity of contractile Ca2+ sensitization in rat arterial smooth muscle

Journal of Physiology

Volumn 590, Issue 21, 2012, Pages 5401-5423

  Kitazawa, Toshio ^a   Kitazawa, Kazuyo ^a  

^a BOSTON BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 5 METHYL 3 [3 [4 [2 (2,2,2 TRIFLUOROETHOXY)PHENYL] 1 PIPERAZINYL]PROPYL] 1H PYRIMIDINE 2,4 DIONE; 8 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ION; MYOSIN LIGHT CHAIN; MYOSIN LIGHT CHAIN PHOSPHATASE; MYOSIN PHOSPHATASE; PHENYLEPHRINE; PHOSPHATASE; PROTEIN KINASE C; PROTEIN KINASE C POTENTIATED PROTEIN PHOSPHATASE INHIBITOR PROTEIN 17KDA; RHO KINASE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTERY DIAMETER; ARTERY MUSCLE; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; DEPHOSPHORYLATION; DYNAMICS; ELECTRIC POTENTIAL; ENZYME INHIBITION; FEMALE; MALE; MEDIAN SACRAL ARTERY; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SENSITIZATION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTILITY; THORACIC AORTA; TIME; VASCULAR SMOOTH MUSCLE;

AMIDES; ANIMALS; ARTERIES; CALCIUM; ENZYME INHIBITORS; FEMALE; MALE; MUSCLE, SMOOTH, VASCULAR; PROTEIN KINASE C; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-1; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; VASOCONSTRICTION;

EID: 84868104219     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2012.241315     Document Type: Article

References (64)

1. Adebiyi A, Zhao G, Narayanan D, Thomas-Gatewood CM, Bannister JP & Jaggar JH (2010). Isoform-selective physical coupling of TRPC3 channels to IP3 receptors in smooth muscle cells regulates arterial contractility. Circ Res 106, 1603-1612.
2. 2+-permeable non-selective cation channels in smooth muscle cells. Cell Calcium 33, 345-356.
3. Ashida T, Schaeffer J, Goldman WF, Wade JB & Blaustein MP (1988). Role of sarcoplasmic reticulum in arterial contraction: comparison of ryanodines's effect in a conduit and a muscular artery. Circ Res 62, 854-863.
4. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR & Cohen P (2007). The selectivity of protein kinase inhibitors: a further update. Biochem J 408, 297-315.
5. Bruns RF, Miller FD, Merriman RL, Howbert JJ, Heath WF, Kobayashi E, Takahashi I, Tamaoki T & Nakano H (1991). Inhibition of protein kinase C by calphostin C is light-dependent. Biochem Biophys Res Commun 176, 288-293.
6. Budzyn K, Paull M, Marley PD & Sobey CG (2006). Segmental differences in the roles of rho-kinase and protein kinase C in mediating vasoconstriction. J Pharmacol Exp Ther 317, 791-796.
7. Clelland LJ, Browne BM, Alvarez SM, Miner AS & Ratz PH (2011). Rho-kinase inhibition attenuates calcium-induced contraction in ß-escin but not Triton X-100 permeabilized rabbit femoral artery. J Muscle Res Cell Motil 32, 77-88.
8. Danthuluri NR & Deth RC (1986). Acute desensitization to angiotensin II: evidence for a requirement of agonist-induced diacylglycerol production during tonic contraction of rat aorta. Eur J Pharmacol 126, 135-139.
9. 2+ sensitization of contraction in arterial smooth muscle. Circ Res 100, 121-129.
10. Docherty JR (2010). Subtypes of functional α1-adrenoceptor. Cell Mol Life Sci 67, 405-417.
11. 1D-adrenoceptor mediated. Eur J Pharmacol 658, 182-186.
12. Dunn SD (1986). Effects of the modification of transfer buffer composition and the renaturation of proteins in gels on the recognition of proteins on Western blots by monoclonal antibodies. Anal Biochem 157, 144-153.
13. Eto M (2009). Regulation of cellular protein phosphatase-1 (PP1) by phosphorylation of the CPI-17 family, C-kinase-activated PP1 inhibitors. J Biol Chem 284, 35273-35277.
14. Goetz AS, King HK, Ward SD, True TA, Rimele TJ & Saussy DL Jr (1995). BMY 7378 is a selective antagonist of the D subtype of α1-adrenoceptors. Eur J Pharmacol 272, R5-R6.
15. 13 in agonist-induced vascular smooth muscle cell contraction. Circ Res 87, 221-227.
16. 2+ sensitization of contraction in vascular smooth muscle. J Biol Chem 278, 1856-1863.
17. Güth K & and Wojciechowski R (1986). Perfusion cuvette for the simultaneous measurement of mechanical, optical and energetic parameters of skinned muscle fibres. Pflugers Arch 407, 552-557.
18. Horiuti K, Somlyo AV, Goldman YE & Somlyo AP (1989). Kinetics of contraction initiated by flash photolysis of caged adenosine triphosphate in tonic and phasic smooth muscles. J Gen Physiol 94, 769-781.
19. Hosoda C, Tanoue A, Shibano M, Tanaka Y, Hiroyama M, Koshimizu TA, Cotecchia S, Kitamura T, Tsujimoto G & Koike K (2005). Correlation between vasoconstrictor roles and mRNA expression of α1-adrenoceptor subtypes in blood vessels of genetically engineered mice. Br J Pharmacol 146, 456-466.
20. Huh YH, Zhou Q, Liao JK & Kitazawa T (2011). ROCK inhibition prevents fetal serum-induced alteration in structure and function of organ-cultured mesenteric artery. J Muscle Res Cell Motil 32, 65-76.
21. Ishizaki T, Maekawa M, Fujisawa K, Okawa K, Iwamatsu A, Fujita A, Watanabe N, Saito Y, Kakizuka A, Morii N & Narumiya S (1996). The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J 15, 1885-1893.
22. Isotani E, Zhi G, Lau KS, Huang J, Mizuno Y, Persechini A, Geguchadze R, Kamm KE & Stull JT (2004). Real-time evaluation of myosin light chain kinase activation in smooth muscle tissues from a transgenic calmodulin-biosensor mouse. Proc Natl Acad Sci U S A 101, 6279-6284.
23. Kamm KE & Stull JT (2001). Dedicated myosin light chain kinases with diverse cellular functions. J Biol Chem 276, 4527-4530.
24. 2+ sensitization of smooth muscle contraction through myosin light chain phosphorylation. J Biol Chem 266, 1708-1715.
25. Kitazawa T, Eto M, Woodsome TP & Brautigan DL (2000). Agonists trigger G protein-mediated activation of the CPI-17 inhibitor phosphoprotein of myosin light chain phosphatase to enhance vascular smooth muscle contractility. J Biol Chem 275, 9897-9900.
26. 2+ sensitization in rabbit smooth muscle. J Physiol 546, 879-889.
27. Kitazawa T, Semba S, Huh YH, Kitazawa K & Eto M (2009). Nitric oxide-induced biphasic mechanism of vascular relaxation via dephosphorylation of CPI-17 and MYPT1. J Physiol 587, 3587-3603.
28. Knepper SM, Buckner SA, Brune ME, DeBernardis JF, Meyer MD & Hancock AA (1995). A-61603, a potent α1-adrenergic receptor agonist, selective for the α1A receptor subtype. J Pharmacol Exp Ther 274, 97-103.
29. Kobayashi E, Nakano H, Morimoto M & Tamaoki T (1989). Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 159, 548-553.
30. Konishi M, Olson A, Hollingworth S & Baylor SM (1988). Myoplasmic binding of fura-2 investigated by steady-state fluorescence and absorbance measurements. Biophys J 54, 1089-1104.
31. Large WA, Saleh SN & Albert AP (2009). Role of phosphoinositol 4, 5-bisphosphate and diacylglycerol in regulating native TRPC channel proteins in vascular smooth muscle. Cell Calcium 45, 574-582.
32. Loirand G, Guérin P & Pacaud P (2006). Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 98, 322-334.
33. Martiny-Baron G, Kazanietz MG, Mischak H, Blumberg PM, Kochs G, Hug H, Marmé D & Schächtele C (1993). Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976. J Biol Chem 268, 9194-9197.
34. Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M, Nakano T, Okawa K, Iwamatsu A & Kaibuchi K (1996). Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J 15, 2208-2216.
35. Methven L, McBride M, Wallace GA & McGrath JC (2009a). The α1B/D-adrenoceptor knockout mouse permits isolation of the vascular α1A-adrenoceptor and elucidates its relationship to the other subtypes. Br J Pharmacol 158, 209-224.
36. Methven L, Simpson PC & McGrath JC (2009b). α1A/B-knockout mice explain the native α1D-adrenoceptor's role in vasoconstriction and show that its location is independent of the other α1-subtypes. Br J Pharmacol 158, 1663-1675.
37. Mueed I, Bains P, Zhang L & Macleod KM (2004). Differential participation of protein kinase C and Rho kinase in α1-adrenoceptor mediated contraction in rat arteries. Can J Physiol Pharmacol 82, 895-902.
38. Murányi A, Derkach D, Erdodi F, Kiss A, Ito M & Hartshorne DJ (2005). Phosphorylation of Thr695 and Thr850 on the myosin phosphatase target subunit: Inhibitory effects and occurrence in A7r5 cells. FEBS Lett 579, 6611-6615.
39. Nakayama K, Kurihara J, Miyajima Y, Ishii K & Kato H (1985). Calcium antagonistic properties of nicardipine, a dihydropyridine derivative assessed in isolated cerebral arteries and cardiac muscle. Arzneimittelforschung 35, 687-693.
40. Nichols RJ, Dzamko N, Hutti JE, Cantley LC, Deak M, Moran J, Bamborough P, Reith AD & Alessi DR (2009). Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J 424, 47-60.
41. Niiro N, Koga Y & Ikebe M (2003). Agonist-induced changes in the phosphorylation of the myosin binding subunit of myosin light chain phosphatase and CPI17, two regulatory factors of myosin light chain phosphatase, in smooth muscle. Biochem J 369, 117-128.
42. 2+. Circ Res 88, 1283-1290.
43. Ohanian V, Ohanian J, Shaw L, Scarth S, Parker PJ & Heagerty AM (1996). Identification of protein kinase C isoforms in rat mesenteric small arteries and their possible role in agonist-induced contraction. Circ Res 78, 806-812.
44. Okumura K, Nishiura T, Awaji Y, Kondo J, Hashimoto H & Ito T (1991). 1, 2-diacylglycerol content and its fatty acid composition in thoracic aorta of diabetic rats. Diabetes 40, 820-824.
45. - channels in response to noradrenaline in vascular myocytes. Br J Pharmacol 104, 1000-1006.
46. Phillips JK, McLean AJ & Hill CE (1998). Receptors involved in nerve-mediated vasoconstriction in small arteries of the rat hepatic mesentery. Br J Pharmacol 124, 1403-1412.
47. Piascik MT, Guarino RD, Smith MS, Soltis EE, Saussy P & Perez DM (1995). The specific contribution of the novel α-1D adrenoceptor to the contraction of vascular smooth muscle. J Pharmacol Exp Ther 275, 1583-1589.
48. Ratz PH, Miner AS & Barbour SE (2009). Calcium-independent phospholipase A2 participates in KCl-induced calcium sensitization of vascular smooth muscle. Cell Calcium 46, 65-72.
49. Rokosh DG & Simpson PC (2002). Knockout of the α1A/C-adrenergic receptor subtype: the α1A/C is expressed in resistance arteries and is required to maintain arterial blood pressure. Proc Natl Acad Sci U S A 99, 9474-9479.
50. 1-adrenergic receptors by vessel bed and age. Circulation 100, 2336-2343.
51. 2+-dependent activation of Rho and Rho kinase in membrane depolarization-induced and receptor stimulation-induced vascular smooth muscle contraction. Circ Res 93, 548-556.
52. Sato K, Ozaki H & Karaki H (1988). Changes in cytosolic calcium level in vascular smooth muscle strip measured simultaneously with contraction using fluorescent calcium indicator fura 2. J Pharmacol Exp Ther 246, 294-300.
53. Shimokawa H & Rashid M (2007). Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci 28, 296-302.
54. Somlyo AP & Somlyo AV (1994). Signal transduction and regulation in smooth muscle. Nature 372, 231-236.
55. 2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 83, 1325-1358.
56. Tai K, Hamaide MC, Debaix H, Gailly P, Wibo M & Morel N (2008). Agonist-evoked calcium entry in vascular smooth muscle cells requires IP3 receptor-mediated activation of TRPC1. Eur J Pharmacol. 583, 135-147.
57. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M & Narumiya S (1997). Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389, 990-994.
58. Williams TJ, Blue DR, Daniels DV, Davis B, Elworthy T, Gever JR, Kava MS, Morgans D, Padilla F, Tassa S, Vimont RL, Chapple CR, Chess-Williams R, Eglen RM, Clarke DE & Ford AP (1999). In vitro α1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel α1A-adrenoceptor selective antagonists. Br J Pharmacol 127, 252-258.
59. 2+ sensitization: Rho-associated kinase-mediated phosphorylation of MYPT1 at Thr-855, but not Thr-697. Biochem J 389, 763-774.
60. Wirth A, Benyó Z, Lukasova M, Leutgeb B, Wettschureck N, Gorbey S, Orsy P, Horváth B, Maser-Gluth C, Greiner E, Lemmer B, Schütz G, Gutkind JS & Offermanns S (2008). G12-G13-LARG-mediated signalling in vascular smooth muscle is required for salt-induced hypertension. Nat Med 14, 64-68.
61. Woodsome TP, Polzin A, Kitazawa K, Eto M & Kitazawa T (2006). Agonist- and depolarization-induced signals for myosin light chain phosphorylation and force generation of cultured vascular smooth muscle cells. J Cell Sci 119, 1769-1780.
62. 2+ release. Circ Res 102, 1118-1126.
63. 1-Adrenoceptor subtypes in the mouse mesenteric artery and abdominal aorta. Br J Pharmacol 134, 1045-1054.
64. Yuan XJ (1997). Role of calcium-activated chloride current in regulating pulmonary vasomotor tone. Am J Physiol Lung Cell Mol Physiol 272, L959-L968.